# Antiseptic Mouth Rinses to Reduce Salivary Viral Load in COVID-19 Patients

> **NCT04707742** · NA · COMPLETED · sponsor: **Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana** · enrollment: 160 (actual)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** Betadine© bucal 100 mg/ml
- **DRUG:** Oximen® 3%
- **DRUG:** Clorhexidine Dental PHB©
- **DRUG:** Vitis Xtra Forte©
- **DRUG:** Distilled Water

## Key facts

- **NCT ID:** NCT04707742
- **Lead sponsor:** Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-15
- **Primary completion:** 2021-09-18
- **Final completion:** 2021-09-30
- **Target enrollment:** 160 (ACTUAL)
- **Last updated:** 2021-10-11

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04707742

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04707742, "Antiseptic Mouth Rinses to Reduce Salivary Viral Load in COVID-19 Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04707742. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*